H. Lundbeck Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Charl van Zyl

Geschäftsführender

DKK 39.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	6.8%
Amtszeit als Geschäftsführer	1.2yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	2.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.7yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Charl van Zyl im Vergleich zu den Einnahmen von H. Lundbeck verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	DKK 3b
Jun 30 2024	n/a	n/a	DKK 3b
Mar 31 2024	n/a	n/a	DKK 2b
Dec 31 2023	DKK 40m	DKK 3m	DKK 2b

Vergütung im Vergleich zum Markt: CharlDie Gesamtvergütung ($USD5.59M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD7.91M).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Charl mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Charl van Zyl (57 yo)

1.2yrs

Amtszeit

DKK 39,600,000

Vergütung

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Charl van Zyl	President & CEO	1.2yrs	DKK 39.60m	keine Daten
Joerg Hornstein	CFO & Executive VP of Corporate Functions	2.3yrs	DKK 10.90m	0.0023% $ 136.7k
Lars Bang	Executive Vice President of Product Development & Supply	5.8yrs	DKK 10.10m	0.038% $ 2.3m
Per Luthman	Executive Vice President of Research & Development	5.8yrs	DKK 11.30m	0.014% $ 841.7k
Tarek Samad	Senior VP & Head of Research	3.5yrs	keine Daten	keine Daten
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	keine Daten	keine Daten
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	keine Daten	keine Daten
Dianne Holto	Executive Vice President of People & Culture	less than a year	keine Daten	keine Daten
Ole Chrintz	Senior Vice President of International Markets	no data	keine Daten	keine Daten
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.8yrs	keine Daten	keine Daten
Bjorn Mogensen	Senior Vice President of Group Finance	2.3yrs	keine Daten	keine Daten
Jose Molinuevo	VP & Head of Experimental Medicine	no data	keine Daten	keine Daten

2.3yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrenes Management: HLBB.FDas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Lars Rasmussen	Independent Chairman	11.8yrs	DKK 1.70m	0.010% $ 606.9k
Lene Skole-Sorensen	Deputy Chairman	9.8yrs	DKK 1.20m	0.0062% $ 372.1k
Jeffrey Berkowitz	Independent Director	6.7yrs	DKK 1.20m	keine Daten
Lars Holmqvist	Director	9.8yrs	DKK 600.00k	0.0076% $ 455.2k
Jakob Riis	Director	1.7yrs	DKK 450.00k	0.0055% $ 328.7k
Ilse Wenzel	Independent Director	3.7yrs	DKK 70.00k	keine Daten
Santiago Arroyo	Independent Director	3.7yrs	DKK 1.00m	keine Daten
Camilla Andersson	Employee Representative Director	2.7yrs	DKK 400.00k	0.00010% $ 6.0k
Dorte Clausen	Employee Representative Director	2.7yrs	DKK 400.00k	0.00011% $ 6.6k
Hossein Armandi	Employee Representative Director	2.7yrs	DKK 400.00k	keine Daten
Lasse Skibsbye	Employee Representative Director	2.7yrs	DKK 400.00k	keine Daten

3.7yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: HLBB.FDie Vorstandsmitglieder gelten als erfahren (3.7 Jahre durchschnittliche Amtszeit).

H. Lundbeck Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S Appoints Charl Van Zyl as New President

Recent updates

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter